|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM150548176 |
| 003 |
DE-627 |
| 005 |
20231223054105.0 |
| 007 |
tu |
| 008 |
231223s2004 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0502.xml
|
| 035 |
|
|
|a (DE-627)NLM150548176
|
| 035 |
|
|
|a (NLM)15380527
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Judkowski, Valeria
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Peptide specific amelioration of T cell mediated pathogenesis in murine type 1 diabetes
|
| 264 |
|
1 |
|c 2004
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 26.10.2004
|
| 500 |
|
|
|a Date Revised 14.11.2007
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a NOD mice spontaneously develop insulitis and type 1 diabetes (T1D) mellitus similar to humans. Insulitis without overt disease occurs in the BDC2.5 TCR-transgenic NOD mice that express the rearranged TCR alpha- and beta-chain genes of a diabetogenic T cell clone reactive to an unknown beta cell autoantigen. A previous study identified an extensive panel of peptides that are highly active in stimulating T cells from transgenic BDC2.5 mice in culture. However, none of these peptides cause active disease in NOD and BDC2.5 animals or in NOD recipients of adoptively transferred BDC2.5 T cells following direct immunization in vivo. We show that direct immunization of transgenic BDC2.5 mice causes many BDC2.5 T cells to become activated and apoptotic. Strikingly, soluble peptides administered to recipients of activated, highly pathogenic BDC2.5 T cells results in protection from disease. These results suggest that high affinity peptide analogues of autoimmune epitopes might be useful as therapeutic modulators in active autoimmune disease
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Research Support, U.S. Gov't, P.H.S.
|
| 650 |
|
7 |
|a Blood Glucose
|2 NLM
|
| 650 |
|
7 |
|a Peptides
|2 NLM
|
| 650 |
|
7 |
|a Vaccines
|2 NLM
|
| 700 |
1 |
|
|a Rodriguez, Enrique
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Pinilla, Clemencia
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Masteller, Emma
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Bluestone, Jeffrey A
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sarvetnick, Nora
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wilson, Darcy B
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 113(2004), 1 vom: 15. Okt., Seite 29-37
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:113
|g year:2004
|g number:1
|g day:15
|g month:10
|g pages:29-37
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 113
|j 2004
|e 1
|b 15
|c 10
|h 29-37
|